The combination of the anti-EGFR antibody cetuximab, olaparib and radiation has been studied in patients with head and neck squamous cell carcinoma [26] and there are currently several phase 1 studies ongoing investigating olaparib in combination with radiotherapy in patients with glioblastoma, lung cancer, breast cancer and head and neck squamous cell carcinoma [27–29]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.